NCT01727726View on ClinicalTrials.gov

A Study of Flexible-dose Brexpiprazole as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder, the Delphinus Trial

PHASE3CompletedINTERVENTIONAL

Enrollment

2,182

Participants

Timeline

Start Date

December 31, 2012

Primary Completion Date

October 17, 2016

Study Completion Date

November 10, 2016

Conditions

Depressive DisorderDepressionDepressive Disorder, MajorMood DisordersMental Disorders

Interventions

DRUG

Brexpiprazole

tablet/capsule

DRUG

Seroquel XR

tablet/capsule

DRUG

Placebo

tablet/capsule

Trial Locations (76)

10003

New York

10168

New York

11000

Belgrade

33015

Miami

33145

Miami

73013

Edmond

92626

Costa Mesa

107076

Moscow

127083

Moscow

163530

Arkhangelsk

190020

Saint Petersburg

191040

Saint Petersburg

192019

Saint Petersburg

199034

Saint Petersburg

Unknown

Birmingham

Phoenix

Little Rock

Bellflower

Beverly Hills

Glendale

Irvine

Redlands

San Diego

Upland

Gainesville

Jacksonville

Jacksonville Beach

Leesburg

Melbourne

Oakland Park

Orange City

Orlando

Decatur

Lake Charles

Baltimore

Belmont

Roslindale

Creve Coeur

Lebanon

Columbus

Dayton

Portland

Salem

Dallas

Murray

Herndon

Richmond

Bellevue

Kirkland

Seattle

Brown Deer

Penticton

Dijon

Douai

Élancourt

Jarnac

Montepellier

Orvault

Achim

Mittweida

Stralsund

Würzburg

Bełchatów

Bydgoszcz

Gdynia

Kielce

Lublin

Tuszyn

Wroclaw

Smolensk

Tonnelniy

Belgrade

Kragujevac

Niš

Novi Kneževac

02472

Watertown

All Listed Sponsors

lead

Otsuka Pharmaceutical Development & Commercialization, Inc.

INDUSTRY

NCT01727726 - A Study of Flexible-dose Brexpiprazole as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder, the Delphinus Trial | Biotech Hunter | Biotech Hunter